Translational Health Research Into Vascular and Neurocognitive Effects of Weight Loss

NCT07592546 · Not yet recruiting

Last updated 2026-05-28

This study tests how weight loss affects inflammation and brain health in adults with mild to moderate obesity.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Non-randomized, open-label (no blinding) treatment study

Participants 240 people Planned (estimated).

Who can join Ages 35–55 · all sexes Healthy volunteers accepted.

Timeline Started 2026-08 · est. completion 2030-06

Where 1 site · Canada

What this study is testing ClinicalTrials.gov NCT07592546 ↗

Description as written by the study sponsor.

The goal of this clinical trial is to learn about the nature of brain abnormalities associated with excess body fat in healthy adults aged 35-55. The main questions it aims to answer are: * Will excessive fat be associated with brain abnormalities on MRI measures? * Will weight loss change brain health on MRI measures? Participants will: * Self-administer study drug, semaglutide, once a week for 80 weeks * Complete metabolic and basic body measurements * Complete cognitive, mood, and dietary assessments * Complete questionnaires * Undergo MRIs

Treatments tested

semaglutide also known as Ozempic, Wegovy Drug

Treatment will be given for 80 weeks. Dose will be escalated from 0.25 mg to a max of 2.4 mg per week.

Main thing measured	Serum C-reactive Protein (CRP)
Sponsor	Alain Dagher
Conditions studied	Class I/II Obesity
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07592546 ↗